VRTX · Vertex Pharmaceuticals Inc / Ma
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 3, 2026TL;DR. Vertex raised full-year 2026 revenue guidance to $13.1–$13.2 billion on 12% Q2 revenue growth, while CASGEVY surged 78% sequentially with a record pediatric FDA approval and JOURNAVX quadrupled year-over-year on expanding payer coverage.
- + Raised full-year 2026 total revenue guidance to $13.1–$13.2 billion from $12.95–$13.1 billion
- + CASGEVY Q2 revenue grew 78% sequentially to $76 million with FDA pediatric approval in record 53 days
- + Povetacicept BLA accepted with November 30 PDUFA, supported by best-in-class Phase 3 RAINIER results
- + Announced $8.8B Crinetics acquisition adding a fifth pillar in rare endocrine with ~$5B peak sales opportunity
- − Non-GAAP operating expenses now expected at high end of $5.65–$5.75B range due to commercial investment in launches
- − Gross margin expected to step down in second half due to product mix and manufacturing investments
- − JOURNAVX gross-to-net normalization delayed to first half of 2027 as PSP utilization exceeds forecast
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VRTX
this stock
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
|
ARGX
Argenx SE
|
$60.40B | +9.3% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VRTX | -4.1% | -9.5% | +14.7% | -3.5% | +11.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -3.9% | -9.1% | +2.5% | -4.4% | -1.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.